The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has received diverse analyst ratings, with a recent shift towards more bullish perspectives. In the last three months, 14 analysts have updated their ratings, showing an increase in bullish ratings and a rise in the average 12-month price target to $88.86 from $80.38. The company's financial performance indicates a 50.41% revenue growth rate, but it struggles with profitability and efficiency, as seen in its net margin, ROE, and ROA figures.
April 22, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies has seen a positive shift in analyst sentiment, with an increase in bullish ratings and a higher average price target. The company's significant revenue growth contrasts with its challenges in profitability and asset utilization.
The increase in bullish ratings and the raised price target suggest a positive short-term impact on ITCI's stock price. However, the underlying financial challenges such as low profitability and efficiency metrics may temper long-term gains. The recent revenue growth is a strong positive, but investors may be cautious due to the profitability and efficiency concerns.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100